Home » Lifestyle » Bayer plans to shift focus away from women’s health drug research
Bayer plans to shift focus away from women’s health drug research
Parents struggle to find medicine for their children
FOX Business correspondent Lydia Hu has the latest on the antibiotic shortage on ‘Varney & Co.’
Bayer, one of the world’s largest pharmaceutical companies, announced on Friday that it will be shifting its focus away from women’s health.
The company plans to put more research efforts into rare diseases, cardiovascular disease, neurology, oncology and immunology.
"When it comes to research and the subsequent clinical phases, we will no longer have an explicit focus on women's health," the head of Bayer's pharmaceuticals unit, Stefan Oelrich, told Reuters.
BE WELL: SPRING-CLEAN YOUR MEDICINE CABINET TO REMOVE EXPIRED DRUGS
However, the company — which makes the common consumer drugs Aleve, Midol, MiraLAX, Alka-Seltzer and Claritin — will continue development of elinzanetant, a non-hormonal medication intended to treat menopausal symptoms.